Transplantation and Tissue Regeneration Flashcards
Autograft
from the same person (CABG, skin graft, blood)
Allograft
from a closely matched individual (close relative or donor)
Isograft
from a genetically identical individual (identical twin)
Hematopoietic stem cell transplant
autologous or allogenic
Solid Organ Sources
- live donor
- cadaveric donor (mostly)
- “brain dead” donor
Transplant Outcomes
- all transplant recipients have a weakened immune system (EXCEPT isografts)
- barriers to success: immunologic rejection, failure to take immuno-suppressive drugs
- immunosuppresion
Immunosuppression
- Induction phase: immediately after transplant, want to make sure transplant tissue has a chance
- Maintenance phase: patient will be immunosuppressed until death
Infections and Transplantation
- may need antibiotic prophylaxis
2. may need to discontinue medication
Malignancies and Transplantation
- cutaneous squamous cell carcinomas (20X)
- virally-induced cancers (HPV, KSHV, EBV)
- post-transplant lymphoproliferative disorders (EBV-induced B cell lesion)
What should be done prior to transplants?
- comprehensive exam
- treat active disease
- extract non-restorable teeth
- oral hygiene instruction
What should be done after transplants?
- defer elective care for three months
- consider antibioitc/antivral prophylaxis
- chlorhexidine??
- watch for infections, bleeding, medication side-effects, adrenal crisis
Hematopoietic Stem-Cell (Bone Marrow) Transplantation
- autologous or allogenic stem cells
2. Usually HLA-matched siblings
Management of Hematopoietic Stem-Cell (Bone Marrow) Transplantation
- must be immunosuppressed (drugs and total body irradiation)
- donor cells infused
- recipient not immunocompressent until donor tissue starts working
Dental Aspects-Bone Marrow Transplant
- oral mucositis (30-50% of pts)
- oral infections, pain, bleeding, gingival hyperplasia, graft-versus-host disease, xerostomia, malignancies
- defer elective dental care for 6 months
Graft-Versus Host Disease
- usually after bone marrow stem cell transfer
- transplanted T-cells recognized HLA antigen–>releases cytokines and TNFa–>destroy tissues (skin, liver, gut)
- chronic –> greater than 100 days
- survival rates drop 42% –> 10%